National Healthcare Quality and Disparities Report
Latest available findings on quality of and access to health care
Data
- Data Infographics
- Data Visualizations
- Data Tools
- Data Innovations
- All-Payer Claims Database
- Healthcare Cost and Utilization Project (HCUP)
- Medical Expenditure Panel Survey (MEPS)
- AHRQ Quality Indicator Tools for Data Analytics
- State Snapshots
- United States Health Information Knowledgebase (USHIK)
- Data Sources Available from AHRQ
Search All Research Studies
AHRQ Research Studies Date
Topics
- Adverse Drug Events (ADE) (2)
- Arthritis (1)
- Behavioral Health (1)
- Chronic Conditions (1)
- Clinical Decision Support (CDS) (1)
- Comparative Effectiveness (1)
- Emergency Department (1)
- Emergency Medical Services (EMS) (1)
- Healthcare Costs (1)
- Healthcare Utilization (1)
- (-) Hepatitis (10)
- Human Immunodeficiency Virus (HIV) (2)
- Medication (6)
- Mortality (1)
- Outcomes (2)
- Patient Adherence/Compliance (2)
- Patient Safety (1)
- Prevention (1)
- Screening (3)
- Shared Decision Making (1)
- U.S. Preventive Services Task Force (USPSTF) (2)
AHRQ Research Studies
Sign up: AHRQ Research Studies Email updates
Research Studies is a compilation of published research articles funded by AHRQ or authored by AHRQ researchers.
Results
1 to 10 of 10 Research Studies DisplayedLaFleur J, Hoop R, Korner E
Predictors of early discontinuation of pegylated interferon for reasons other than lack of efficacy in United States veterans with chronic hepatitis C.
The researchers determined whether selected patient characteristics predicted discontinued therapy for reasons other than lack of efficcacy (non-LOE) using national databases of U.S. veterans. They found that predictors of greatest magnitude included comorbidities of myocardial infarction/congestive heart failure, renal disease, platelets 100/mm or more, Black race, albumin 3.5 mg/dl or more, sleep aid use, and poor persistence with antidepressants and antihypertensive agents.
AHRQ-funded; HS018582.
Citation: LaFleur J, Hoop R, Korner E .
Predictors of early discontinuation of pegylated interferon for reasons other than lack of efficacy in United States veterans with chronic hepatitis C.
Gastroenterol Nurs 2015 Nov-Dec;38(6):417-28. doi: 10.1097/sga.0000000000000214.
.
.
Keywords: Chronic Conditions, Hepatitis, Medication, Patient Adherence/Compliance
Butt AA, Yan P, Shaikh OS
Virologic response and haematologic toxicity of boceprevir- and telaprevir-containing regimens in actual clinical settings.
This study sought to quantify treatment response, tolerability and occurrence of haematologic adverse events among persons treated with boceprevir (B0C)- and telaprevir (TPV)-containing regimens and compare them with historic controls treated with pegylated interferon/ribavirin (PEG/RBV) in actual clinical settings. It found that use of BOC- and TPV-containing regimens is superior to PEG/RBV for treatment of HCV genotype 1-infected persons.
AHRQ-funded; HS018372.
Citation: Butt AA, Yan P, Shaikh OS .
Virologic response and haematologic toxicity of boceprevir- and telaprevir-containing regimens in actual clinical settings.
J Viral Hepat 2015 Sep;22(9):691-700. doi: 10.1111/jvh.12375..
Keywords: Adverse Drug Events (ADE), Hepatitis, Medication
Mabry-Hernandez I, Lewis P
AHRQ Author: Mabry-Hernandez I
Screening for hepatitis B virus infection in nonpregnant adolescents and adults.
This paper presents a case study and quiz regarding a 35-year-old man whose parents were born in southeast Asia. Although he was born in the United States, he. does not have any vaccination records from his childhood. During an office visit, he mentions that a relative was recently diagnosed with hepatitis B virus (HBV) infection and asks whether he should be screened. Correct answers are based on the U.S. Preventive Services Task Force Recommendation Statement.
AHRQ-authored.
Citation: Mabry-Hernandez I, Lewis P .
Screening for hepatitis B virus infection in nonpregnant adolescents and adults.
Am Fam Physician 2015 Aug 15;92(4):301-2..
Keywords: U.S. Preventive Services Task Force (USPSTF), Screening, Hepatitis, Prevention
Pho MT, Jensen DM, Meltzer DO
Clinical impact of treatment timing for chronic hepatitis C infection: a decision model.
The researchers developed a decision model to quantify the trade-offs between immediate, interferon-containing therapy and delayed, interferon-free therapy for patients with chronic, genotype 1 HCV infection. They found that compared to one-time immediate treatment with the interferon-containing regimen, delayed treatment with the interferon-free regimen in 1 year resulted in longer life expectancy.
AHRQ-funded; HS022433.
Citation: Pho MT, Jensen DM, Meltzer DO .
Clinical impact of treatment timing for chronic hepatitis C infection: a decision model.
J Viral Hepat 2015 Aug;22(8):630-8. doi: 10.1111/jvh.12412..
Keywords: Clinical Decision Support (CDS), Shared Decision Making, Hepatitis, Medication, Outcomes
Burton MJ, Curtis JR, Yang S
Safety of biologic and nonbiologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis B virus infection: a retrospective cohort study.
The researchers evaluated the safety of current treatment regimens for patients with rheumatoid arthritis (RA) and HBV in a large US cohort. They found a low rate of hepatotoxicity among a large cohort of US veterans with RA and HBV infection who were prescribed conventional RA therapies. Also, there were comparable rates of hepatotoxicity between biologic and nonbiologic disease-modifying anti-rheumatic drugs.
AHRQ-funded; HS023710.
Citation: Burton MJ, Curtis JR, Yang S .
Safety of biologic and nonbiologic disease-modifying antirheumatic drug therapy in veterans with rheumatoid arthritis and hepatitis B virus infection: a retrospective cohort study.
Arthritis Res Ther 2015 May 22;17:136. doi: 10.1186/s13075-015-0628-z..
Keywords: Arthritis, Patient Safety, Medication, Hepatitis, Adverse Drug Events (ADE)
Crowell TA, Berry SA, Fleishman JA
AHRQ Author: Fleishman JA
Impact of hepatitis coinfection on healthcare utilization among persons living with HIV.
The purpose of this study is to characterize the impact of hepatitis coinfection on utilization of primary HIV care, mental health, and inpatient services. It found no difference in primary HIV care utilization according to hepatitis serostatus. However, patients with HIV/HCV coinfection demonstrated higher rates of mental health visits than any of the other groups examined.
AHRQ-authored; AHRQ-funded; ; 290201100007C.
Citation: Crowell TA, Berry SA, Fleishman JA .
Impact of hepatitis coinfection on healthcare utilization among persons living with HIV.
J Acquir Immune Defic Syndr 2015 Apr;68(4):425-31. doi: 10.1097/qai.0000000000000490..
Keywords: Human Immunodeficiency Virus (HIV), Hepatitis, Healthcare Utilization, Behavioral Health
Galbraith JW, Franco RA, Donnelly JP
Unrecognized chronic hepatitis C virus infection among baby boomers in the emergency department.
The researchers described early experience with integrated opt-out HCV antibody (Ab) screening of medically stable baby boomers presenting to an urban academic ED. They observed high prevalence of unrecognized chronic HCV infection in this series of baby boomers presenting to the ED, highlighting the ED as an important venue for high-impact HCV screening and linkage to care.
AHRQ-funded; HS013852.
Citation: Galbraith JW, Franco RA, Donnelly JP .
Unrecognized chronic hepatitis C virus infection among baby boomers in the emergency department.
Hepatology 2015 Mar;61(3):776-82. doi: 10.1002/hep.27410.
.
.
Keywords: U.S. Preventive Services Task Force (USPSTF), Hepatitis, Screening, Emergency Medical Services (EMS), Emergency Department
Montenovo MI, Dick AA, Hansen RN
Donor hepatitis C sero-status does not impact survival in liver transplantation.
The researchers sought to assess the impact of both donor and recipient HCV status on patient and graft survival. They found that the use of HCV+ grafts in HCV+ recipients is not associated with worse outcomes. They conclude that with the increase in HCV+patients awaiting an organ, more consideration should be given to HCV+ donors.
AHRQ-funded; HS021686.
Citation: Montenovo MI, Dick AA, Hansen RN .
Donor hepatitis C sero-status does not impact survival in liver transplantation.
Ann Transplant 2015 Jan 22;20:44-50. doi: 10.12659/aot.892530..
Keywords: Hepatitis, Comparative Effectiveness, Outcomes, Mortality
Zhang S, Rust G, Cardarelli K
Adherence to highly active antiretroviral therapy impact on clinical and economic outcomes for Medicaid enrollees with human immunodeficiency virus and hepatitis C coinfection.
The purpose of this study was to quantify the clinical and economic benefits of adherence to anti-retroviral therapy (ART), with a special focus on the subset of Medicaid enrollees with both HIV and HCV coinfection. It found that high-adherence to ART among Medicaid-enrolled patients with HIV and HCV coinfection is achievable – over 60 percent of such patients in this data-set had over 95 percent adherence to their ART.
AHRQ-funded; HS022444.
Citation: Zhang S, Rust G, Cardarelli K .
Adherence to highly active antiretroviral therapy impact on clinical and economic outcomes for Medicaid enrollees with human immunodeficiency virus and hepatitis C coinfection.
AIDS Care 2015;27(7):829-35. doi: 10.1080/09540121.2015.1021745..
Keywords: Hepatitis, Human Immunodeficiency Virus (HIV), Patient Adherence/Compliance, Medication
Kim DD, Hutton DW, Raouf AA
Cost-effectiveness model for hepatitis C screening and treatment: Implications for Egypt and other countries with high prevalence.
The researchers examined the cost-effectiveness of screening and treatment for HCV infection for asymptomatic, average-risk adults using a Markov decision analytic model. They found that, in Egypt, implementing a screening program using triple-therapy treatment (sofosbuvir with pegylated interferon and ribavirin) was dominant compared with no screening because it would have lower total costs and improve health outcomes.
AHRQ-funded; HS013853.
Citation: Kim DD, Hutton DW, Raouf AA .
Cost-effectiveness model for hepatitis C screening and treatment: Implications for Egypt and other countries with high prevalence.
Glob Public Health 2015;10(3):296-317. doi: 10.1080/17441692.2014.984742..
Keywords: Hepatitis, Screening, Healthcare Costs, Medication